Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | SCN4A | P35499 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888881 | 0.86 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2SCN4AMEN1 | |
| SCHEMBL889391 | 0.85 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2SCN4AMEN1 | |
| SCHEMBL12591857 | 0.81 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2SCN4AMEN1 | |
| SCHEMBL2609433 | 0.81 | SMN1; SMN2 (0.67) | RAB9ANPC1SMN1; SMN2SCN4AMEN1 | |
| SCHEMBL2609448 | 0.80 | NPC1 (0.51) | RAB9ANPC1SMN1; SMN2SCN4AMEN1 | |
| SCHEMBL20049512 | 0.80 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2SCN4AMEN1 | |
| SCHEMBL19398571 | 0.80 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2SCN4AMEN1 | |
| SCHEMBL15801269 | 0.80 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2SCN4AMEN1 | |
| SCHEMBL1309315 | 0.80 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2SCN4AMEN1 | |
| SCHEMBL11796059 | 0.80 | SMN1; SMN2 (0.61) | RAB9ANPC1SMN1; SMN2SCN4AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230148448-A9 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148448-A9 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| US-20230029557-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-02-02 | — | — | US | disclosed |
| US-11530211-B2 | Dihydroindolizinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-20 | — | — | US | disclosed |
| US-9163017-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140213601-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8541424-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100168138-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-7713962-B2 | Neurofibrillary labels | WISTA LABORATORIES LTD. (SG) | 2010-05-11 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080219929-A1 | Neurofibrillary labels | WISTA LABORATORIES, LTD. | 2008-09-11 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-7335652-B2 | Neurofibrillary labels | WISTA LABORATORIES LTD. (SG) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168138-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | RAB9A 1535/4885NPC1 81/4885SMN1; SMN2 4141/4885 |
| US-20230029557-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | ACP1, PTPRCAP, PTPRO | RAB9A 3126/4885NPC1 3822/4885SMN1; SMN2 4733/4885 |
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | ACP1, PTPRCAP, PTPRO | RAB9A 3126/4885NPC1 3822/4885SMN1; SMN2 4733/4885 |
| US-20140213601-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | RAB9A 1535/4885NPC1 81/4885SMN1; SMN2 4141/4885 |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | RAB9A 2515/4885NPC1 37/4885SMN1; SMN2 4591/4885 |
| US-20230148448-A9 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | RAB9A 3000/4885NPC1 2801/4885SMN1; SMN2 4156/4885 |
| US-11530211-B2 | Dihydroindolizinone derivative | INSR, GPR119, IAPP | RAB9A 1776/4885NPC1 1231/4885SMN1; SMN2 2978/4885 |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | HLA-DRB1, CD74, HLA-C | RAB9A 3054/4885NPC1 952/4885SMN1; SMN2 1178/4885 |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | STAT1, STAT3, STAT5A | RAB9A 1035/4885NPC1 4078/4885SMN1; SMN2 2923/4885 |
| US-20080219929-A1 | Neurofibrillary labels | MAPT, PSEN1, PSEN2 | RAB9A 2505/4885NPC1 3325/4885SMN1; SMN2 575/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | RAB9A 1096/4885NPC1 1283/4885SMN1; SMN2 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.